FDA Objects To Claims Based On Low-Quality Evidence In DTC Ads
Executive Summary
FDA's Division of Drug Marketing, Advertising and Communications recently used a series of untitled letters to emphasize that the evidence used to make claims in a promotion piece must be of sufficient quality
You may also be interested in...
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
Genentech Fields Overstated Claim For Boniva, DDMAC Says
The ad for the osteoporosis drug - featuring actress Sally Field and running in Parade magazine - was improperly based on a post-hoc responder analysis, DDMAC says.